Novi Pharmaceuticals International Holdings Limited (Novi Pharmaceuticals) recorded revenues of approximately HK$50.2 million in 2013, down approximately 44.1% from approximately HK$89.8 million in the previous year. Gross profit was approximately HK$12.9 million, down approximately 2.3% from approximately HK$13.2 million a year earlier. Company owners accounted for a net loss of approximately HK$22.2 million, a decrease of approximately 71.5% from the previous year's loss of approximately HK$77.9 million. The Board of Directors does not propose the payment of a final dividend for the year ended 31 December 2013. On 31 December 2013, the Group's asset and debt ratio was zero. The Group's main business is the distribution and trade of pharmaceutical products in China and the provision of marketing and promotion services.

Novi Pharmaceuticals International Holdings Limited (Novi Pharmaceuticals) recorded revenues of approximately HK$50.2 million in 2013, down approximately 44.1% from approximately HK$89.8 million in the previous year. Gross profit was approximately HK$12.9 million, down approximately 2.3% from approximately HK$13.2 million a year earlier. Company owners accounted for a net loss of approximately HK$22.2 million, a decrease of approximately 71.5% from the previous year's loss of approximately HK$77.9 million. The Board of Directors does not propose the payment of a final dividend for the year ended 31 December 2013. On 31 December 2013, the Group's asset and debt ratio was zero. The Group's main business is the distribution and trade of pharmaceutical products in China and the provision of marketing and promotion services.